Boehringer Ingelheim’s Alteplase receives risk/benefit endorsement from MHRA

Boehringer Ingelheim has announced that its specialist stroke medicine Alteplase has had its risk/benefit profile confirmed by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

An expert working group review on behalf of the regulator has reconfirmed that the benefits of Alteplase outweigh the risks when used within its licence, meaning patients and doctors can continue to have faith in its effectiveness.

This follows an extensive and thorough review of more than a decade of clinical experience and evidence supporting the therapy, which is the only clot buster licensed for the treatment of acute ischaemic stroke.

Professor Jorg Kreuzer, head of cardiovascular medicine at Boehringer Ingelheim, said: “The news from the MHRA expert working group confirms that our medicine can play a vital role in improving the lives of patients."

This comes after the company's drug Ofev was recommended in international treatment guidelines for use in idiopathic pulmonary fibrosis patients earlier this month.